Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Allylescaline
Подписчиков: 0, рейтинг: 0
Names | |
---|---|
Preferred IUPAC name
2-{3,5-Dimethoxy-4-[(prop-2-en-1-yl)oxy]phenyl}ethan-1-amine | |
Other names
2-[4-(Allyloxy)-3,5-dimethoxyphenyl]ethan-1-amine
2-[4-(Allyloxy)-3,5-dimethoxyphenyl]ethanamine | |
Identifiers | |
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider |
|
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C13H19NO3 | |
Molar mass | 237.299 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Allylescaline (4-allyloxy-3,5-dimethoxyphenethylamine) is a lesser-known psychedelic drug. It is closely related in structure to mescaline. Allylescaline was first synthesized by Otakar Leminger in 1972. The compound was later synthesized by Alexander Shulgin and further described in his book PiHKAL. The dosage range is listed as 20–35 mg, and the duration 8–12 hours. Allylescaline produces an entactogenic warmth, an entheogenic effect, and a feeling of flowing energy. Very little data exists about the pharmacological properties, metabolism, and toxicity of allylescaline.
Legal status
Allylescaline is illegal in Sweden as of January 2016.